The Oncology Institute, Inc. (STLN) Stock Forecast
STLN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $9.40 average of analyst targets
- Upside to target
- +46.2% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.07
- 52-week range
- $2.38 – $7.05
STLN analyst ratings
5 analystsNumber of analysts at each rating.
STLN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
STLN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.07 | −$0.04 | −$0.14 | +65.7% | 5 |
| Current fiscal year (2026) | −$0.16 | −$0.21 | −$0.11 | −$0.54 | +70.0% | 5 |
| Next fiscal year (2027) | $0.00 | −$0.06 | $0.10 | −$0.16 | +100.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
STLN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $168.7M | $164.9M | $171.6M | +23.5% | 4 |
| Current fiscal year (2026) | $665.0M | $659.9M | $669.5M | +32.3% | 4 |
| Next fiscal year (2027) | $884.0M | $856.0M | $915.4M | +32.9% | 4 |
STLN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
STLN revenue: reported and forecast
STLN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.04 | −$0.05 | −$0.05 | −$0.05 | −$0.05 | +33.3% | 0 up · 2 down |
| Current fiscal year (2026) | −$0.14 | −$0.16 | −$0.16 | −$0.16 | −$0.16 | +17.4% | 0 up · 4 down |
| Next fiscal year (2027) | −$0.03 | $0.00 | $0.00 | $0.00 | $0.00 | −100.0% | 3 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
STLN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; STLN beat in 2 of 5.
What analysts expect from STLN
5 analysts cover Oncology Institute; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.40, 46.2% above the latest close of $6.43. Analysts expect earnings of −$0.16 per share for 2026, +70.0% from a year earlier. For 2027 the average estimate is $0.00 per share on revenue of $884.0 million. Oncology Institute beat the EPS estimate in 2 of the last 5 quarters.
Related: STLN income statement, STLN key metrics, STLN chart. See the STLN stock overview for the latest quote and news.
STLN forecast FAQ
What is Oncology Institute's price target?
The average analyst price target for Oncology Institute is $9.40, 46.2% above the latest close of $6.43.
Is Oncology Institute a buy, hold or sell?
Of 5 analysts covering Oncology Institute, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Oncology Institute's EPS forecast?
Analysts forecast −$0.16 per share for 2026 (range −$0.21 to −$0.11); for 2027 the estimate is $0.00.
What is Oncology Institute's revenue forecast?
The average revenue estimate for 2026 is $665.0 million, growth of 32.3%; for 2027 it is $884.0 million.
When does Oncology Institute report earnings?
Oncology Institute is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.07.
Does Oncology Institute usually beat earnings estimates?
Oncology Institute reported EPS at or above the analyst estimate in 2 of the last 5 quarters.